E-mail
Print
Text
Johnson & Johnson invests in Alzheimer’s drug project
CommentsJohnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer’s disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.
The two will cooperate to complete research on two injected drugs to stop progression of the mind-robbing disease and on a vaccine to prevent the buildup of plaque in the brain that causes increasing memory loss, confusion, wandering and aggression. The deal, announced Thursday, sent Elan’s U.S. shares up 60 cents, or 8.6 percent, to close at $7.60.
Comments
JOIN THE DISCUSSION
We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service.
Comments are displayed newest first. If you would like to read a thread from beginning to end, select "Oldest first" from the drop down menu.
We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service.
Comments are displayed newest first. If you would like to read a thread from beginning to end, select "Oldest first" from the drop down menu.
|
|
• Preps:
|
